Abstract
GABAA receptors are critical for inhibitory neurotransmission. Variants in genes encoding these receptors are involved in the pathophysiology of both common and rare epilepsy syndromes. Variant effects on channel biophysical function, broadly classified as gain-of-function (GOF) or loss-of-function (LOF), are associated with key clinical characteristics and treatment response. Understanding and predicting variant effects is therefore essential to improve care for individuals with GABAA-related disorders. Here, we present GABAA receptor functional variant effect prediction using multi-task phenotypic learning (GENTLY).
We collected clinical data from 505 affected individuals with 272 (likely) pathogenic GABAA receptor variants across GABRA1, GABRB2, GABRB3, and GABRG2. All variants were evaluated with in-vitro electrophysiology using receptor assemblies that reflect heteropentamer composition in heterozygous carriers. Variants were annotated with features based on sequence (e.g. physicochemical properties, conservation), structure (e.g. binding sites, domains), and phenotypes represented by 8185 HPO terms. We trained separate models on all features and without clinical features. Model performance was estimated using ablation, cross-validation, and external validation on a further 197 individuals with 138 (likely) pathogenic GABAA receptors variants.
Our models enable highly accurate prediction of GOF/LOF in GABAA (AU-ROC 0.863-0.946), outperforming state-of-the-art genome-wide predictors (LoGoFunc: AU-ROC 0.495; evo2: AU-ROC 0.559-0.755) and clinical decision-making (decision tree: AU-ROC 0.823). Model scores correlated strongly with GABA sensitivity (r = -0.77, p < 0.001). Predictions were consistent with expert-based structure-function hypotheses: variants located in transmembrane domains were more likely GOF (p < 0.001), and variants in GABA binding sites were more likely LOF (p < 0.001). Predictions on variants from population databases behaved as expected: 13,389 population variants were similar to functionally neutral variants, and predictions from (likely) pathogenic ClinVar variants were similar to GOF/LOF variants. Our model may provide additional evidence for 10-29% of 2,295 variants in ClinVar. Lastly, we show that a simple k-nearest neighbour algorithm can predict likely clinical characteristics only from variant information (median Lin similarity 0.754 IQR 0.161).
We demonstrate accurate variant effect prediction in GABAA receptors with rigorous validation across the largest dataset of functionally tested variants to date. Our predictions correlate with continuous electrophysiological measurements not directly used during training and conform to known structure-function relationships, supporting their biological plausibility. These predictions may facilitate timely diagnosis, precision treatment, and prognosis of individuals with GABAA receptor related disorders. A web interface, precomputed scores, and ACMG-calibrated score thresholds for all possible variants are openly available.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported the Else Kroener Research School PRECISE.net, the rare disease network Treat-ION (BMBF, 01GM2210A), the Research Unit FOR-2715 (DFG, LE1030/16-2 & LE1030/23-1) and the MINT-Clinician Scientist program of the Medical Faculty Tuebingen (DFG, 493665037). This work utilized compute resources at the Tuebingen Machine Learning Cloud, DFG FKZ INST 37/1057-1 FUGG. The Lundbeck Foundation R383-2022-276 (RSD, SO, SEK, RSM, PKA) supported the clinical and functional part of this project.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was approved by the Institutional Review Board (EMN-2024-01998) of the Danish Epilepsy Center.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
Model predictions for all possible missense variants are openly available on Zenodo at DOI 10.5281/zenodo.17800749, including annotations of the score ranges and evidence calibration thresholds shown below. An interactive website including our model and cohort summary statistics is openly available (https://nddportals.shinyapps.io/gabaportal/). Raw clinical and experimental data that support the findings of this study are available from the corresponding author upon reasonable request.





